Study on MTM1: Potential Drug Target and Biomarker (G4534)

Target Name: MTM1

NCBI ID: G4534

MTM1

Study on MTM1: Potential Drug Target and Biomarker

MTM1 (Phosphatidylinositol-3,5-bisphosphate 3-phosphatase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the signaling pathway known as the PI3K/Akt pathway, which is involved in a wide range of physiological processes, including cell growth, differentiation, and survival. In recent years, researchers have become increasingly interested in investigating the role of MTM1 in human diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the key challenges in studying MTM1 is its difficulty to target. due to its high stability and its role in multiple signaling pathways, it has been difficult to develop small molecules that can specifically interact with it. However, recent studies have identified a new potential drug target for MTM1, which is the 3-phosphatase activity of MTM1. This activity can be inhibited by small molecules such as negative allosterics, which are drugs that bind to a protein and prevent it from interacting with its target.

Another approach to studying MTM1 is its role as a biomarker. due to its involvement in multiple signaling pathways, it is possible to use MTM1 as a proxy for the activity of other signaling pathways, such as the PI3K/Akt pathway. Researchers have been able to use this to study the effects of drugs on various physiological processes, including cell growth, differentiation, and survival. This has led to the development of new treatments for a wide range of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In addition to its potential as a drug target and biomarker, MTM1 is also of interest due to its role in the regulation of cellular processes that are important for human health. The PI3K/Akt pathway is involved in the regulation of cellular processes that are important for cell growth, differentiation, and survival, and MTM1 plays a key role in this pathway. Studies have shown that MTM1 activity can be modulated by various factors, including nutrients, toxins, and diseases. This suggests that MTM1 may be a useful target for the development of new treatments for a wide range of diseases.

Overall, MTM1 is a protein that is of interest due to its role in the PI3K/Akt pathway and its potential as a drug target and biomarker. Further research is needed to fully understand its role in human diseases and to develop new treatments based on this protein.

Protein Name: Myotubularin 1

Functions: Lipid phosphatase which dephosphorylates phosphatidylinositol 3-monophosphate (PI3P) and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) (PubMed:11001925, PubMed:10900271, PubMed:12646134, PubMed:14722070). Has also been shown to dephosphorylate phosphotyrosine- and phosphoserine-containing peptides (PubMed:9537414). Negatively regulates EGFR degradation through regulation of EGFR trafficking from the late endosome to the lysosome (PubMed:14722070). Plays a role in vacuolar formation and morphology. Regulates desmin intermediate filament assembly and architecture (PubMed:21135508). Plays a role in mitochondrial morphology and positioning (PubMed:21135508). Required for skeletal muscle maintenance but not for myogenesis (PubMed:21135508). In skeletal muscles, stabilizes MTMR12 protein levels (PubMed:23818870)

The "MTM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets